India Ratings upgrades Sai Life Sciences to IND A
Sai Life Sciences (SAILIFE) said India Ratings has upgraded its credit rating to IND A. The company is valued at about ₹40,971 crore.
What happened
In a filing with the BSE on 13 November 2026 at 09:45 PM, Sai Life Sciences (SAILIFE) said that India Ratings has upgraded its credit rating to IND A.
From the filing: "Ltd. ( " India Ratings " ) has upgraded the credit rating of the Company on 13 th November 2026."
Company snapshot
Sai Life Sciences is a mid-cap company in the Healthcare sector, with a market value of about ₹40,971 crore.
The stock last traded at ₹1,928.8, against a 52-week range of ₹783.9–₹1,941.8 (0.7% below the high).
Before this filing the shares had moved +30.4% over the month and +31.1% over three months. Average daily turnover over the last 20 sessions was about ₹303 crore.
Promoters held 34.50% at the end of Q2 FY27, down 0.03% points from the previous quarter. Foreign institutions owned 19.91% and domestic institutions 32.32%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q2 FY26 | 537 | 83.8 | 4.01 |
| Q3 FY26 | 556 | 100.4 | 4.77 |
| Q4 FY26 | 602 | 104.2 | 4.93 |
| Q1 FY27 | 554 | 73.3 | 3.46 |
| Q2 FY27 | 659 | 98.3 | 4.63 |
What history shows
BCEIE has no earlier credit rating filing from this company on record since May 2026.
Across 34 similar disclosures by other Healthcare companies, shares moved +0.0% on average the next day and +1.4% over five days; 59% of them rose the next day.
Market-wide, 1,468 credit rating filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 48% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Whether other agencies take a similar view on the company's credit.
In the news
Recent coverage elsewhere (links open the original publisher):
- Sai Life soars 10%, hits record high on strong Q2 earnings
- Sai Life Sciences Ltd (NSE:SAILIFE) (Q2 2027) Earnings Call Highlights: 23% Revenue Growth, ...
- Sai Life Sciences Q2 2027 Earnings Call Is Live
- Sai Life Sciences Limited Set to Approve Q2 FY27 Results
- Divis Laboratories, Gland Pharma, Sai Life Sciences shares hit 52-week highs; here's why
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.